Inhalation Drug Recalled Due to Sterility Assurance Failure
Cipla recalls Budesonide Inhalation Suspension ampules due to inability to assure sterility. Affected lots GA20080, GA20081, and GA20094 expire January 2024.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall with lack of sterility assurance for an inhalation drug. While no illnesses or injuries have been reported, non-sterile inhalation medications pose serious risk of infection to the lungs.
Plain-English summary
Cipla USA Inc. is recalling Budesonide Inhalation Suspension 0.25mg/2mL (Lot numbers GA20080, GA20081, GA20094; expiration January 2024), a prescription respiratory medication supplied as single-dose ampules. The company distributed 641,160 ampules nationwide.
The recall was issued because the manufacturer cannot assure that all units in these lots meet the required sterility standards for inhalation products. Budesonide inhalation suspension is administered directly to the lungs, where sterility is a critical safety requirement.
The affected product was distributed nationwide in the United States and Puerto Rico. Patients who have received medication from these lots should consult their healthcare provider.
Patients should not use affected units and should contact their healthcare provider for a replacement or alternative medication. Report any adverse effects to the FDA or the manufacturer.
The recalled product
- Product
- BUDESONIDE (BUDESONIDE)
- Brand
- BUDESONIDE
- Manufacturer
- CIPLA
- Category
- Drug — Inhalation Suspension
- Affected units
- 641,160
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Lot #s: GA20080
- GA20081
- GA20094
- Exp. 01/2024
Distribution
Related recalls
Same brand · BUDESONIDE
- HighBudesonide inhalation ampules contain black and brown specks and particles
FDA (Drugs) · 2026-06-17
- HighBudesonide inhalation ampoules recalled after leakage and empty ampoule complaint
FDA (Drugs) · 2025-07-30
- HighFDA Recalls Budesonide Extended-Release Tablets for Failed Dissolution
FDA (Drugs) · 2024-02-07
Same manufacturer · CIPLA
See all →- HighPrescription inhalation drug recalled due to sterility assurance failure
FDA (Drugs) · 2022-10-12
- HighDifluprednate Eye Drops Recalled for Defective Container Compromising Sterility
FDA (Drugs) · 2022-09-14
- HighDifluprednate Eye Drops Recalled for Defective Container Sterility Risk
FDA (Drugs) · 2022-09-14
- HighDifluprednate eye drops recalled for defective container closure affecting sterility
FDA (Drugs) · 2022-08-17
- HighFDA Recalls Cipla Difluprednate Eye Drops for Defective Container Caps
FDA (Drugs) · 2022-07-27
Same hazard · lack of sterility
See all →- HighRohto Cooling Eye Drops Max Strength Recalled Due to Sterility Concerns
FDA (Drugs) · 2026-07-29
- HighRohto Cooling Eye Drops Recalled Due to Lack of Assurance of Sterility
FDA (Drugs) · 2026-07-29
- SevereCleviprex Injectable Emulsion Recall Due to Sterility Assurance Concerns
FDA (Drugs) · 2026-07-22
- SeverePemetrexed for Injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-07-15
- SevereAzacitidine for Injection Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2026-07-15